Marksans Pharma
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Marksans Pharma is poised for growth, driven by strategic capacity expansions and a shift towards high-value consumer healthcare products. Management's focus on operational excellence and market penetration in regulated regions, particularly North America and Europe, underpins a stable revenue outlook. The company's recent capacity expansion in Goa and commitment to R&D in Advanced Drug Delivery Systems are expected to enhance margins and support long-term growth. Despite facing external challenges such as inflationary pressures and geopolitical risks, Marksans' diversified geographic footprint and strong cash position provide a buffer. Vista's forecast anticipates revenue growth consistent with historical performance, alongside improving margins, aligning with the company's strategic priorities. The favorable industry dynamics, including improving pricing power and a projected CAGR of 7.37%, further bolster the outlook. Over the next 12-24 months, key opportunities include deepening retail channel penetration and scaling manufacturing capacity, while watchpoints include potential raw material shortages and trade policy shifts that could impact margins
Why We Like This Stock
- Strategic capacity expansion and R&D focus on high-value consumer healthcare products enhance revenue and margin potential
- Strong cash position allows for disciplined investments and acquisitions, supporting long-term growth objectives
- Favorable industry dynamics, including improving pricing power and a projected CAGR of 7.37%, bolster the company's growth outlook
Things To Watch Out For
- Inflationary pressures and geopolitical risks may impact input costs and margins in the near term
- Potential raw material shortages could disrupt production and affect revenue growth
- Shifting trade policies may pose challenges for market expansion, particularly in the US and Europe
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 2,177 | 2,623 | 2,951 | 3,319 | 3,852 |
| Profit Before Tax (Cr.) | 424 | 503 | 561 | 711 | 802 |
| PBT Margin | 19.5% | 19.2% | 19.0% | 21.4% | 20.8% |
| Net Profit (Cr.) | 310 | 377 | 420 | 533 | 598 |
| Earnings Per Share | 6.8 | 8.3 | 9.2 | 11.7 | 13.2 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Choice Equity | ► Hold | 290 | 29-May-2026 |
Company Overview
Show Company Profile
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.